Heron Therapeutics Overview
Heron Therapeutics (HRTX) has a ROE of -492.89%, below the Healthcare sector average of 21.28%.
Get informed when a big investor buys or sells
+ Follow-492.89%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Heron Therapeutics (HRTX) currently reports a ROE of -492.89%. That is below the Healthcare sector average of 21.28%. Use the charts on this page to explore Heron Therapeutics's ROE history and peer comparisons.
Heron Therapeutics's ROE of -492.89% is lower than the Healthcare sector average of 21.28%. That is roughly 2416.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Heron Therapeutics's current -492.89% should be judged against Healthcare norms (sector average: 21.28%) and against HRTX's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -492.89%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 21.28%. From there, open related valuation or income-statement pages for Heron Therapeutics, and consider following HRTX for alerts when major investors trade the stock.
Heron Therapeutics is classified in the Healthcare sector. On ROE, it currently shows -492.89% versus a sector average near 21.28%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing HRTX with unrelated industries.
